Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States
Introduction
Chronic hepatitis C virus (HCV) infection affects 170 million people worldwide, including 2.7 million of U.S. individuals [1], [2], [3]. Although a great deal of progress has been made [3], [4], [5], [6], [7], factors affecting disease progression and development of cirrhosis in these patients remain incompletely defined.
Hepatic steatosis is a well-documented histological feature during HCV infection [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18]. Most studies [8], [10], [11], [12], [13], [14], [15], [19] have suggested that obesity is associated with steatosis in patients with chronic hepatitis C (CHC). However, a general threshold of body mass index (BMI) for steatosis and association of BMI with grade of steatosis remain to be determined.
Besides obesity, type 2 diabetes mellitus (DM) and hypertriglyceridemia have also been associated with hepatic steatosis in patients with non-alcoholic fatty liver disease [20], [21], [22], [23], [24]. Increased frequency of type 2 DM has been reported in patients with CHC [25], [26]. A recent study included 7.7% patients with DM, but could not directly associate DM with hepatic steatosis [19]. In addition, the effect of hypertriglyceridemia on hepatic steatosis in HCV-infected patients has not been systematically examined. Therefore, it is important to determine whether DM and/or hypertriglyceridemia alone, or in combination with obesity, contribute to development of hepatic steatosis in these patients.
Expression of HCV proteins has been associated with hepatic steatosis in transgenic mice [27], [28]. These results were further supported by findings that HCV genotype 3a (HCV-3a) is associated with both higher prevalence and grade of hepatic steatosis in patients with CHC [9], [14], [15], [19], [29], [30], [31]. However, this association remains to be further defined [16].
Several studies have reported an association of steatosis with advanced hepatic fibrosis in patients with CHC [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]. However, it remains unknown whether a higher grade of steatosis is more associated with a higher stage of hepatic fibrosis. In addition, it remains controversial whether BMI affects progression of fibrosis directly [8]. A few studies have reported that hepatic steatosis is associated with higher levels of alanine aminotransferase (ALT) and histological activity index (HAI) [8], [9], [19], but these findings were not supported by other studies [11], [12], [16]. Thus, it is necessary to re-examine these issues in a large cohort of HCV-infected patients.
The aims of this retrospective study were to determine the prevalence of and the risk factors for hepatic steatosis and to assess the association of being overweight/obese and steatosis with activity and progression of CHC in U.S. patients.
Section snippets
Patient population
The present study retrospectively included 324 consecutive patients from two Liver Clinics at Loma Linda VA Medical Center (n=112) and Loma Linda University Medical Center (n=212) between July 1999 and April 2002. The study protocol was approved and informed consent was exempted by the institutional review boards from both medical centers. Inclusion criteria were: (1) positive HCV RNA reverse transcription polymerase chain reaction (RT-PCR) for at least 6 months; (2) a liver biopsy to stage
Baseline demographic findings
The baseline demographic data are summarized in Table 1. Of the 307 patients with recorded BMI, the mean BMI was 28.5±5.3 (17–47) kg/m2. Overweight was seen in 122/307 (39.7%) cases, and obesity was seen in 116/307 (37.8%) patients. Overall, 238/307 (77.5%) patients were overweight or obese. In 250 patients with documented information of drinking, 69.6% reported a past history of alcohol use. In 189 patients with recorded duration of sobriety, 32.8% have been sobered for 6–12 months and 67.2%
Discussion
The present study investigated a large cohort of US patients with CHC and demonstrated that the frequency of steatosis was as high as 66.0% in these patients. Hourigan et al. reported that 20.0% of Australian patients with CHC have grade II/III steatosis [6]. Using the same scoring system, grade II/III steatosis was seen in 30.0% of our patients with CHC. Therefore, hepatic steatosis, especially a higher grade of steatosis, is a very common presentation in U.S. patients with CHC.
Although it is
Acknowledgements
The authors are indebted to Dr. Pramil N. Singh for his invaluable comments on statistical analysis. Part of this work was published as an abstract in Hepatology 2002; 36: 349A and presented in 53 AASLD annual meeting in November 2002 in Boston. This work was supported by a grant from the Division of Gastroenterology and Hepatology, Loma Linda University School of Medicine (K-Q. H.).
References (40)
- et al.
Epidemiology of chronic hepatitis C infection in sub-Saharan Africa
Lancet Infect Dis
(2002) - et al.
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients
Gastroenterology
(1997) - et al.
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
Hepatology
(2001) - et al.
Host- and disease-specific factors affecting steatosis in chronic hepatitis C
J Hepatol
(1998) - et al.
Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation
J Hepatol
(2001) - et al.
Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response
Hepatology
(2002) Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always
Hepatology
(2002)- et al.
Steatosis in chronic hepatitis: relative contribution of obesity, diabetes mellitus, and alcohol
Hepatology
(2002) - et al.
Non-alcoholic fatty liver disease: an agenda for clinical research
Hepatology
(2002) - et al.
Non-alcoholic steatohepatitis: an expanded clinical entity
Gastroenterology
(1994)
Steatosis and liver cancer in transgenic mice expressing the structural and non-structural proteins of hepatitis C virus
Gastroenterology
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3
J Hepatol
Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study
Hepatology
Non-alcoholic steatohepatitis: a proposal for grading and staging the histologic lesions
Am J Gastroenterol
Fatty liver (FL) in chronic hepatitis B carriers may affect the interpretation of alanine aminotransferase (ALT) elevations
J Hepatol
Prevalence of hepatitis C virus infection in the United States
N Engl J Med
Management of Hepatitis C: 2002-June 10–12, 2002
Hepatology
Natural history of hepatitis C
Hepatology
Natural history of hepatitis C: its impact on clinical management
Hepatology
The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States
Hepatology
Cited by (136)
Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
2021, Complementary Therapies in MedicineSignificant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared With Other Ethnic Groups
2019, Clinical Gastroenterology and HepatologyCitation Excerpt :In the general population, age-matched studies have reported a higher prevalence of NALFD in Hispanics than NHWs or NHBs.27–29 National studies have also shown that NAFLD accelerates progression of HCV-related liver disease and this effect appears to be significantly greater among Hispanics.30 Studies of liver biopsy specimens of patients with chronic HCV have reported a higher prevalence of steatosis in Hispanics vs NHWs that was associated with higher fibrosis stage and faster fibrosis progression over time among Hispanics.7
Grade of donor liver microvesicular steatosis does not affect the postoperative outcome after liver transplantation
2017, Hepatobiliary and Pancreatic Diseases InternationalPatatin-like phospholipase domain containing-3 gene (PNPLA3) I148M polymorphism and liver damage in chronic hepatitis C Egyptian patients
2015, Egyptian Journal of Medical Human GeneticsScheuer’s Liver Biopsy Interpretation
2015, Scheuer's Liver Biopsy Interpretation